

## SUPPLEMENTARY MATERIAL

### **Liver function tests and fibrosis scores in a rural population in Africa: a cross-sectional study to estimate the burden of disease and associated risk factors**

Geraldine A O'Hara, Jolyne Mokaya, Jeffrey P Hau, Louise O Downs, Anna L McNaughton<sup>2</sup>, Alex Karabarinde, Gershim Asiki, Janet Seeley, Philippa C Matthews, Robert Newton

---

#### **CONTENTS**

**Suppl Table 1:** Origin, reference ranges and clinical significance of liver function tests (LFTs)

**Suppl Table 2:** Scores to estimate liver fibrosis, calculated from liver function tests

**Suppl Table 3:** Description of characteristics of study participants with liver function test (LFT) results from the Ugandan General Population Cohort (N=8,099)

**Suppl Table 4:** Median and inter-quartile range for each liver function test with the population divided by risk factors

**Suppl Fig 1:** Distribution of liver function tests in Uganda General Population Cohort.

**Suppl Fig 2:** Odds ratio for deranged ALT, AST, APRI, GPR and AST/ALT among participants grouped by sex and age.

**Suppl Fig 3:** Proportion of Uganda General Population cohort reporting alcohol consumption among individuals with and without AST/ALT ratio >2

**Suppl Fig 4:** Proportion of Uganda General Population Cohort with elevated GGT, according to AST/ALT ratio. (A) males, with upper limit of normal GGT=61 (B) females, with upper limit of normal GGT=36. P-values by Fisher's Exact Test

**Suppl Fig 5:** Proportion of Uganda General Population Cohort with blood borne virus (BBV) infection, according to GPR score. P-value by Fisher's Exact Test, showing significant enrichment of BBV infection among individuals with elevated GPR score >0.32.

**Suppl data Table 1: Origin, reference ranges and clinical significance of liver function tests (LFTs) identified from published literature (7,10,54).** LRR: local reference range (derived from populations in Africa); ARR: American reference range.

Biomarker	Origin	LRR	ARR	Common causes of derangement (Abnormal elevation for all markers other than albumin)
Alanine transferase (ALT)	Highest concentration in hepatocytes (small amounts in other tissues: muscles, adipose tissues, intestines, colon, prostate, and brain)	8 – 61 U/L	Male: 10 - 55 U/L Female: 7 - 30 U/L	<ul style="list-style-type: none"> <li>Acute / chronic viral hepatitis (EBV/CMV/HBV/HCV/HEV)</li> <li>Alcoholism</li> <li>Non-alcoholic fatty liver disease (NAFLD)</li> <li>Drugs: antipsychotics, antibiotics, statins.</li> <li>Autoimmune hepatitis</li> <li>Ischaemic liver damage</li> <li>Haemochromatosis</li> <li>Wilson's disease</li> <li>Coeliac disease</li> </ul>
Aspartate transferase (AST)	Hepatocytes Cardiac muscle Skeletal muscle	14 - 60 U/L	Male: 10 - 40 U/L Female: 9 - 32 U/L	<ul style="list-style-type: none"> <li>The causes listed for raised ALT.</li> <li>As AST is abundant in skeletal, cardiac and smooth muscle it may also be elevated in patients with cardiac disease, myositis or muscular dystrophy.</li> </ul>
Alkaline phosphatase (ALP)	Liver (from biliary epithelium) Bone Placenta	48 - 164 U/L	Male: 45 - 115 U/L Female: 30–100 U/L	<ul style="list-style-type: none"> <li>Bile duct obstruction</li> <li>Primary biliary cirrhosis</li> <li>Primary sclerosing cholangitis</li> <li>Drugs: Antibiotics, antiepileptics, MAOI's</li> <li>Bone growth, and bone disease</li> <li>Pregnancy</li> <li>Hepatic congestion from right sided heart failure</li> </ul>
Gamma-glutamyl-transferase (GGT)	Liver Kidney Pancreas Intestine Prostate	Nil available	Male: 8 - 61 U/L Female: 5 - 36 U/L	<ul style="list-style-type: none"> <li>Obesity</li> <li>Hepatobiliary disease</li> <li>Pancreatic disease</li> <li>Alcoholism</li> <li>Drugs: carbamazepine, phenytoin, and barbituates.</li> </ul>
Bilirubin (BR)	Red blood cells Liver Bone marrow	2.9 – 37.0 mmol/L	0 – 17 mmol/L	<p><b>Unconjugated hyperbilirubinaemia</b></p> <ul style="list-style-type: none"> <li>Haemolysis (sickle cell disease and malaria particularly relevant)</li> <li>Ineffective erythropoiesis</li> <li>Gilbert's syndrome</li> <li>Drugs: Rifampicin</li> </ul> <p><b>Conjugated hyperbilirubinaemia</b></p> <ul style="list-style-type: none"> <li>Liver disease</li> <li>Biliary obstruction</li> </ul>

Albumin (Alb)	Liver; acute phase marker.	35 – 52 g/L	35 – 55 g/L	Lowered in association with: <ul style="list-style-type: none"> <li>• Chronic liver disease.</li> <li>• Nephrotic syndrome,</li> <li>• Protein losing enteropathy,</li> <li>• Protein Energy Malnutrition</li> <li>• Hypercatabolic states, e.g. in association with malignancy, infection.</li> <li>• Congestive cardiac failure</li> </ul>
---------------	----------------------------	-------------	-------------	--

LRR: Local Reference Ranges derived from a study by Karita et al (19). All ranges are for both male and female.

ARR: American Reference Ranges derived from MGH Clinical Laboratories.

MAOI: Monoamine oxidase inhibitors

\*No local references were available for Gamma GT

<sup>4</sup>Bilirubin measurement is total Bilirubin concentration measured in *mmol/L*

**Suppl Table 2: Scores to estimate liver fibrosis, calculated from liver function tests**

<b>Score</b>	<b>Formula</b>	<b>Threshold used to predict fibrosis</b>	<b>Sensitivity and specificity of fibrosis threshold (derived from previous studies)</b>
<b>APRI</b>	$(\text{AST}/\text{ULN AST} \times 100) / \text{platelet count}$	0.7	Sensitivity: 77% Specificity: 72% Derived from meta-analysis of studies of HCV infection (26).
<b>FIB-4</b>	$(\text{Age in years} \times \text{AST}) / (\text{platelet count} \times \sqrt{\text{ALT}})$	3.25	Specificity: 97% Positive predictive value: 65% Derived from HIV/HCV coinfecting individuals (27).
<b>GPR</b>	$(\text{GGT}/\text{ULN of GGT}/\text{platelet count}) \times 100$	0.32	Optimal cut-off value for predicting significant fibrosis. Derived from individuals with chronic HBV infection in The Gambia (14).
<b>RPR</b>	Red cell distribution width%/ platelet count	0.825	Sensitivity: 63.1% Specificity: 85.5% Positive predictive value: 65% Derived from individuals with chronic HBV infection in China (28).
<b>S-index</b>	$(1000 \times \text{GGT}) \div (\text{platelet count} \times \text{Albumin}^2)$	0.3	Specificity: 94% Positive predictive value: 87% Accuracy: 68% Derived from individuals with chronic HBV infection in Egypt (29).

AST = Aspartate transaminase at u/l, ULN = upper limit of normal,

ALT = Alanine transaminase at u/l

GGT= Glutamyltransferase at u/l, ULN = upper limit of normal,

Platelet count at  $10^9/\text{L}$

**Suppl Table 3: Description of characteristics of study participants with liver function test (LFT) results from the Ugandan General Population Cohort (N=8,099)**

<i>Variable</i>	<i>Total n(%)</i>	<i>Male n(%)</i>	<i>Female n(%)</i>	<i>p value<sup>1</sup></i>
	8,099 (100.00)	3,542 (100.00)	4,557 (100.00)	
<b>Age Group</b>				
16-19	2,481 (30.6)	1,268 (35.8)	1,213 (26.6)	<0.001
20-29	1,508 (18.6)	618 (17.5)	890 (19.5)	0.02
30-39	1,349 (16.6)	510 (14.4)	839 (18.4)	<0.001
40-49	1,095 (13.5)	454 (12.8)	641 (14.0)	0.10
50-59	744 (9.2)	315 (8.9)	429 (9.4)	0.42
>60	922 (11.4)	377 (10.8)	545 (12.0)	0.06
<b>Max Education</b>				
None	759 (9.4)	208 (5.9)	551 (12.1)	<0.001
Primary	5,165 (63.8)	2,380 (67.2)	2,785 (61.1)	<0.001
Secondary	1,839 (22.7)	793 (22.3)	1,046 (23.0)	0.54
Higher Level	336 (4.1)	161 (4.5)	175 (3.8)	0.11
<b>SES<sup>2</sup></b>				
Lower	2,309 (34.6)	1,048 (35.7)	1,261 (33.6)	0.08
Middle	2,175 (32.5)	945 (32.1)	1,230 (32.8)	0.59
Upper	2,203 (32.9)	944 (32.1)	1,259 (33.6)	0.22
<b>HIV Status</b>				
Negative	7,483 (92.5)	3,331 (94.1)	4,152 (91.2)	
Positive	608 (7.5)	208 (5.9)	400 (8.8)	<0.001
<b>Hepatitis B</b>				
Negative	7,878 (97.3)	3,420 (96.6)	4,458 (97.8)	
Positive	220 (2.7)	122 (3.4)	98 (2.2)	<0.001
<b>Hepatitis C</b>				
Negative	8,086 (99.8)	3,533 (99.7)	4,553 (99.9)	
Positive	13 (0.2)	9 (0.3)	4 (0.1)	0.06
<b>BMI<sup>3</sup></b>				
Normal weight	5,095 (65.1)	2,259 (64.4)	2,836 (65.7)	0.23
Underweight	1,772 (22.7)	1,075 (30.6)	697 (16.1)	<0.001
Overweight/Obese	960 (12.2)	175 (5.0)	785 (18.2)	<0.001
<b>Alcohol Consumption<sup>4</sup></b>				
Never drinkers	5,180 (64.0)	2,120 (59.9)	3,060 (67.2)	
Drinkers	2,919 (36.0)	1,422 (40.1)	1,497 (32.8)	<0.001

<sup>1</sup> p-value calculated to determine whether significant difference between males and females in each category using chi-square test

<sup>2</sup> Socio-economic Score (SES) derived from conducting Principle Component Analysis (PCA) on a statistical software using variables relating to household infrastructure and property ownership

<sup>3</sup> Body Mass Index (BMI) Classification according to WHO (weight/height<sup>2</sup>: kg/m<sup>2</sup>): Underweight (<18.5 kg/m<sup>2</sup>), Normal weight (18.5 – 24.99 kg/m<sup>2</sup>), Overweight (25.0 – 29.99 kg/m<sup>2</sup>), Obese (>30.0 kg/m<sup>2</sup>)

<sup>4</sup> Alcohol consumption based on self-reported history of consuming alcohol vs never consuming alcohol

**Suppl Table 4: Median and inter-quartile range for each liver function test, with the population divided by risk factors.**

	ALT <sup>1,2</sup> Median (IQR)	AST <sup>1</sup> Median (IQR)	ALP <sup>1</sup> Median (IQR)	GGT <sup>1</sup> Median (IQR)	Total BR <sup>1</sup> Median (IQR)	FIB-4 <sup>1</sup> Median (IQR)	APRI <sup>1,3</sup> Median (IQR)	GPR <sup>1</sup> Median (IQR)	S-Index <sup>3</sup> Median (IQR)
<b>Sex</b>									
Male	19.4 (15.6-25.0)	27.9 (23.9-33.5)	97.1 (74.3-209.9)	21.6 (15.5-32.8)	8.9 (5.9-14.1)	0.90 (0.49-1.57)	0.24 (0.18-0.33)	0.17 (0.12-0.30)	0.06 (0.04-0.11)
Female	16.4 (13.0-21.3)	23.1 (19.8-27.4)	89.5 (68.5-123.2)	16.9 (12.3-24.4)	6.9 (4.8-10.4)	0.81 (0.47-1.40)	0.18 (0.14-0.24)	0.21 (0.15-0.32)	0.04 (0.03-0.07)
<i>p-value</i>	***	***	***	***	***	**	***	***	***
<b>Age</b>									
<19	17.8 (14.5-22.1)	26.5 (22.6-31.4)	218.8 (134.5-306.0)	16.2 (12.6-21.2)	7.26 (4.97-11.4)	0.42 (0.33-0.54)	0.19 (0.15-0.25)	0.15 (0.11-0.21)	0.04 (0.03-0.05)
20-29	18.0 (13.8-23.8)	23.8 (19.9-28.5)	82.4 (66.8-102.8)	17.7 (12.5-25.3)	8.59 (5.69-13.9)	0.65 (0.50-0.90)	0.19 (0.15-0.30)	0.18 (0.13-0.27)	0.05 (0.03-0.07)
30-39	18.3 (13.9-24.5)	24.1 (20.1-29.6)	74.8 (59.9-94.5)	20.0 (13.7-32.0)	7.88 (5.28-12.7)	1.02 (0.78-1.34)	0.21 (0.16-0.29)	0.23 (0.16-0.39)	0.06 (0.04-0.11)
40-49	18.4 (14.3-24.1)	25.1 (21.0-31.1)	74.7 (60.3-90.0)	22.0 (14.8-36.7)	7.78 (5.08-12.1)	1.36 (1.03-1.80)	0.23 (0.16-0.32)	0.25 (0.17-0.45)	0.07 (0.04-0.14)
50-59	18.3 (14.2-23.6)	25.7 (21.5-32.0)	83.2 (71.6-99.4)	24.1 (16.7-38.1)	7.41 (5.41-11.4)	1.66 (1.32-2.29)	0.22 (0.17-0.32)	0.29 (0.19-0.48)	0.08 (0.05-0.13)
>60	15.4 (12.3-20.0)	24.9 (21.4-29.9)	89.5 (73.9-107.9)	23.7 (16.2-35.7)	7.16 (4.90-10.4)	2.20 (1.61-3.23)	0.20 (0.16-0.29)	0.26 (0.18-0.43)	0.08 (0.04-0.12)
<i>p-value</i>	***	***	***	***	***	***	***	***	***
<b>Alcohol</b>									
No	17.6 (13.9-22.4)	24.9 (21.1-29.7)	103.0 (74.3-204.3)	17.3 (12.8-23.7)	7.57 (5.16-12.0)	0.61 (0.40-1.08)	0.20 (0.15-0.27)	0.17 (0.12-0.26)	0.04 (0.03-0.07)
Yes	17.9 (13.9-24.0)	25.2 (21.4-31.8)	83.0 (67.1-103.9)	23.2 (15.6-38.9)	7.77 (5.24-12.1)	1.40 (0.88-2.14)	0.22 (0.17-0.32)	0.26 (0.17-0.46)	0.07 (0.04-0.14)
<i>p-value</i>	**	***	***	***	ns	***	***	***	***
<b>BMI<sup>2</sup></b>									
Normal	17.9 (14.3-22.8)	27.5 (23.3-32.8)	185.2 (90.9-297.0)	18.5 (13.7-26.0)	7.09 (4.85-11.2)	0.53 (0.35-1.38)	0.21 (0.16-0.29)	0.17 (0.12-0.27)	0.04 (0.03-0.08)
Under-weight	17.9 (14.1-23.2)	25.0 (21.3-30.1)	88.1 (69.1-122.5)	18.7 (13.7-27.8)	8.00 (5.39-12.8)	0.90 (0.51-1.52)	0.21 (0.15-0.39)	0.20 (0.14-0.32)	0.05 (0.03-0.08)
Over-weight	18.0 (13.9-23.1)	22.7 (19.4-27.0)	81.3 (65.2-99.1)	21.8 (14.8-31.5)	7.28 (5.12-10.9)	0.96 (0.61-1.42)	0.18 (0.14-0.25)	0.23 (0.16-0.38)	0.06 (0.04-0.09)
<i>p-value</i>	ns	***	***	***	***	***	***	***	ns
<b>HIV status</b>									
Negative	17.6 (13.9-22.7)	25.0 (21.2-30.0)	93.7 (71.8-151.3)	18.4 (13.4-26.6)	7.89 (5.40-12.4)	0.82 (0.46-1.46)	0.20 (0.15-0.28)	0.19 (0.13-0.29)	0.05 (0.03-0.08)
Positive	19.4 (14.9-26.5)	27.1 (22.3-33.5)	83.2 (65.1-107.8)	30.6 (16.7-58.3)	5.06 (3.53-7.66)	1.21 (0.76-1.70)	0.23 (0.18-0.34)	0.44 (0.20-0.79)	0.11 (0.05-0.20)
<i>p-value</i>	***	***	***	***	***	***	***	***	***
<b>HBV status</b>									
Negative	17.7 (13.9-22.7)	25.1 (21.1-30.2)	92.6 (71.3-144.8)	18.6 (13.5-27.6)	7.62 (5.19-12.0)	0.84 (0.47-1.47)	0.20 (0.15-0.27)	0.19 (0.13-0.31)	0.05 (0.03-0.08)
Positive	22.0 (15.8-29.2)	28.2 (23.0-39.0)	91.9 (71.6-131.5)	23.5 (15.4-37.6)	8.76 (5.34-13.4)	1.01 (0.55-1.80)	0.25 (0.19-0.48)	0.32 (0.17-0.52)	0.11 (0.06-0.20)
<i>p-value</i>	***	***	ns	***	*	ns	***	***	***

<sup>1</sup> ALT - Alanine Transaminase, AST - Aspartate Transaminase, GGT - Gamma-glutamyl transpeptidase, ALP - Alkaline Phosphatase, TB -

Total Bilirubin, FIB-4 - fibrosis 4, APRI - AST to Platelet Ratio Index, GPR - GGT to platelet ratio, IQR - inter-quartile range


<sup>2</sup> Body Mass Index (BMI) Classification according to WHO (weight/height<sup>2</sup>: kg/m<sup>2</sup>): Underweight (<18.5 kg/m<sup>2</sup>), Normal weight (18.5 – 24.99 kg/m<sup>2</sup>), Overweight (25.0 – 29.99 kg/m<sup>2</sup>), Obese (>30.0 kg/m<sup>2</sup>)

<sup>3</sup> An S-index score of >0.3 is suggestive of liver fibrosis


# APRI score calculated using ULN of AST using African reference range

p-value significance level: \* = (p<0.05), \*\* = (p<0.01), \*\*\* = (p<0.001), ns = (p>0.05)

**Suppl Fig 1: Distribution of liver function tests in Uganda General Population Cohort.** Top row: ALT -alanine transferase, AST – aspartate transferase, GGT – gamma glutamyl transferase. Bottom row: BR – bilirubin, ALP – alkaline phosphatase.




**Suppl Fig 2: Odds ratio for deranged ALT, AST, APRI, GPR and AST/ALT among participants of te General Population Cohort in Uganda. Data grouped by sex and age, by multivariate analysis.**






**Suppl Fig 3:** Proportion of Uganda General Population Cohort reporting alcohol consumption among individuals with and without AST/ALT ratio >2



**Suppl Fig 4: Proportion of Uganda General Population Cohort with elevated GGT, according to AST/ALT ratio.** (A) males, with upper limit of normal GGT=61 (B) females, with upper limit of normal GGT=36. P-values by Fisher's Exact Test



**Suppl Fig 5: Proportion of Uganda General Population Cohort with blood borne virus (BBV) infection, according to GPR score.** P-value by Fisher's Exact Test, showing significant enrichment of BBV infection among individuals with elevated GPR score >0.32.

